Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) Non Operating Income (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Non Operating Income for 14 consecutive years, with -$661000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income fell 178.97% year-over-year to -$661000.0, compared with a TTM value of $302000.0 through Dec 2025, down 92.22%, and an annual FY2025 reading of $1.8 million, down 53.88% over the prior year.
  • Non Operating Income was -$661000.0 for Q4 2025 at Enanta Pharmaceuticals, down from -$282000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $1.9 million in Q2 2023 and bottomed at -$661000.0 in Q4 2025.
  • Average Non Operating Income over 5 years is $709550.0, with a median of $667500.0 recorded in 2024.
  • The sharpest move saw Non Operating Income soared 620.39% in 2023, then plummeted 178.97% in 2025.
  • Year by year, Non Operating Income stood at $258000.0 in 2021, then soared by 284.88% to $993000.0 in 2022, then dropped by 13.7% to $857000.0 in 2023, then dropped by 2.33% to $837000.0 in 2024, then tumbled by 178.97% to -$661000.0 in 2025.
  • Business Quant data shows Non Operating Income for ENTA at -$661000.0 in Q4 2025, -$282000.0 in Q3 2025, and $667000.0 in Q2 2025.